[123I]β-甲基-对-碘苯基-十五烷酸([123I]BMIPP),用于心肌脂肪酸代谢的核医学成像,积聚在癌细胞中。然而,积累的机制仍然未知。因此,本研究旨在阐明[123I]BMIPP在癌细胞中的积累和积累机制。我们比较了[123I]BMIPP在癌细胞中的积累与[18F]FDG的积累,发现[123I]BMIPP的积累比[18F]FDG高得多。在存在磺基琥珀酰亚胺油酸酯(SSO)的情况下评估[123I]BMIPP的积累,CD36抑制剂,和lipofermata,脂肪酸转运蛋白(FATP)抑制剂,在低温条件下,在依托莫西的存在下,肉碱棕榈酰转移酶I(CPT1)抑制剂。结果表明,在H441,LS180和DLD-1细胞中,[123I]BMIPP积累在SSO和脂质铁的存在下减少,提示FATPs和CD36参与[123I]BMIPP在癌细胞中的摄取。[123I]在所有癌细胞系中的BMIPP积累在4°C下与37°C下相比显着降低,并且在所有癌细胞系中存在依托莫昔尔时增加,表明[123I]BMIPP在癌细胞中的积累是代谢依赖性的。在使用移植有LS180细胞的荷瘤小鼠进行的生物分布研究中,[123I]BMIPP不仅在LS180细胞中而且在正常组织和器官(包括血液和肌肉)中高度积累。[123I]BMIPP的肿瘤与肠或大肠比率与[18F]FDG相似,在体内研究中,[123I]BMIPP给药后30分钟内,肿瘤与大肠的比率超过1.0。[123I]BMIPP通过CD36和FATP被癌细胞吸收,并通过CPT1掺入线粒体。因此,[123I]BMIPP可能对脂肪酸代谢激活的癌症成像有用,比如结肠癌。然而,需要开发基于[123I]BMIPP化学结构类似物的新型成像放射性示踪剂。
[123I]β-methyl-p-iodophenyl-pentadecanoic acid ([123I]BMIPP), which is used for nuclear medicine imaging of myocardial fatty acid metabolism, accumulates in cancer cells. However, the mechanism of accumulation remains unknown. Therefore, this study aimed to elucidate the accumulation and accumulation mechanism of [123I]BMIPP in cancer cells. We compared the accumulation of [123I]BMIPP in cancer cells with that of [18F]FDG and found that [123I]BMIPP was a much higher accumulation than [18F]FDG. The accumulation of [123I]BMIPP was evaluated in the presence of sulfosuccinimidyl oleate (SSO), a CD36 inhibitor, and lipofermata, a fatty acid transport protein (FATP) inhibitor, under low-temperature conditions and in the presence of etomoxir, a carnitine palmitoyl transferase I (CPT1) inhibitor. The results showed that [123I]BMIPP accumulation was decreased in the presence of SSO and lipofermata in H441, LS180, and DLD-1 cells, suggesting that FATPs and CD36 are involved in [123I]BMIPP uptake in cancer cells. [123I]BMIPP accumulation in all cancer cell lines was significantly decreased at 4 °C compared to that at 37 °C and increased in the presence of etomoxir in all cancer cell lines, suggesting that the accumulation of [123I]BMIPP in cancer cells is metabolically dependent. In a biological distribution study conducted using tumor-bearing mice transplanted with LS180 cells, [123I]BMIPP highly accumulated in not only LS180 cells but also normal tissues and organs (including blood and muscle). The tumor-to-intestine or large intestine ratios of [123I]BMIPP were similar to those of [18F]FDG, and the tumor-to-large-intestine ratios exceeded 1.0 during 30 min after [123I]BMIPP administration in the in vivo study. [123I]BMIPP is taken up by cancer cells via CD36 and FATP and incorporated into mitochondria via CPT1. Therefore, [123I]BMIPP may be useful for imaging cancers with activated fatty acid metabolism, such as colon cancer. However, the development of novel imaging radiotracers based on the chemical structure analog of [123I]BMIPP is needed.